Organization Profile

You just read:

iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema

News provided by

iCo Therapeutics Inc.

Jun 09, 2014, 08:00 ET